NEO-CYT positions MDNA11 in a frontline neoadjuvant melanoma setting, where immunotherapy before surgery may help generate deeper and more durable anti-tumor immune responses Up to 80 patients with ...
MedPage Today on MSN
Melanoma vaccine halves risk of recurrence, metastasis over 5 years
Adjuvant approach will need confirmation from ongoing phase III trial, says expert ...
At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction in the risk of ...
Jennifer Frederick was in the best shape of her life in 2023, so when she felt a small lump in her groin area after a week of workouts. She thought it was just a pulled muscle, but a month later, the ...
Work presented this week at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and also published in the ...
The agency will now treat Replimune’s RP1 as ‘an urgent matter.’ ...
Dermatomyositis is an autoimmune inflammatory muscle disease that is linked to cancer in approximately one third of the cases. The most commonly associated cancers are ovarian, lung, gastric, ...
Christy Redican grew up in Connecticut, spending summers sailing and playing tennis. “I was a sun worshipper,” she said. “I ...
Moderna and Merck present 5-year data for intismeran autogene in combo with Keytruda in patients with high-risk stage III/IV melanoma following complete resection at 2026 ASCO mee ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results